Master Capital Services Limited has Submitted to the Exchange a copy of Letter of Offer.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.1 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nectar Lifesciences Limited has filed a Letter of Offer to buyback up to 3 crore (3,00,00,000) fully paid-up equity shares of face value ₹1 each, representing 13.38% of the existing paid-up equity capital. The buyback price is fixed at ₹27 per share, aggregating to a maximum of ₹81 crore (excluding transaction costs). The buyback size represents 9% of the total paid-up equity share capital and free reserves as per audited financials for FY ended March 31, 2025. The Record Date is Wednesday, December 24, 2025, with the buyback window opening on December 31, 2025 and closing on January 6, 2026. Shareholders are entitled to tender 25 shares for every 103 shares held on the record date. Promoters have declared they will not participate in the buyback, and the offer will be funded from securities premium account and free reserves (no borrowed funds).
Eligible shareholders can tender their shares at ₹27 per share during the 5-working-day window. Since promoters are not participating, the buyback is entirely from public shareholders' holdings. The buyback is within SEBI-prescribed limits (under 10% of paid-up capital and free reserves) and may provide price support. The total outflow of up to ₹81 crore will reduce free reserves/securities premium of the company.